Today I offer a brief glimpse of seven reports in the past six months on eye problems associated with - but not proven to be caused by - the use of GLP-1 drugs
These medications: Microdosing has become a practical approach for many patients seeking to balance effectiveness with affordability
Interventions with compounds like PEBG, sesamol, Q3G, Triphala, ginger, and pterostilbene consistently demonstrated elevations in key metabolitesincluding acetate, propionate, butyrate, isobutyrate, valerate, and otherswhich correlated with enhanced memory performance, reduced neuroinflammation, and improved gut-brain axis functionality [21, 24, 33, 36,37,38, 41]
The effect typically improves significantly once steady state is reached around week four, as trough levels are substantially higher at that point